Silicon BioDevices (SBD) was founded in 2009 to commercialize the next generation point-of-care (POC) diagnostic technology. The core technology arose out of work at UC Berkeley’s Sensor and Actuator Center (BSAC), and was developed by SBD along with the remaining components of the company's complete POC test system. Financing for development has come from several sources, including the NIH, NASA, and private investors.
In late 2012, around the time the details of the Nokia Sensing XCHALLENGE were announced, the functional prototype was completed. And the match was clear. XPRIZE and Nokia were promoting exactly the sort of innovation that SBD was focused on performing. Moreover, the focus on mobile technology highlights the very aspects of the SBD assay platform that differentiate it from other, traditional and even novel assay platforms, which require readers that include part of the assay functionality and cannot be eliminated or replaced by a mobile device. SBD is currently working to characterize and optimize this technology.
About Team Leader
Tayson Siegel has spent the last seven years as a medical device entrepreneur and a professional in the venture-backed startup community. After taking a strong interest in entrepreneurship as a student, he worked at SVB Capital, where he participated in the investment process and worked with the LP relations team to characterize the investor landscape, and Vision Capital, where he studied the impacts of environmental disruptions and environmental business strategy on equity valuation. He received his Bachelor’s degree in Mathematics and Economics from UC Berkeley and completed a certificate in the Management of Innovation and Technology at UC Berkeley’s Center for Entrepreneurship and Technology. In 2008 Tayson joined the other founders of Silicon BioDevices to help turn an exciting academic research project into a company with a major societal impact.
|Tayson Siegel||Octavian Florescu||Tracie Martin|